Novo Nordisk insulin Ryzodeg passes Japan review
COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Monday its Ryzodeg insulin had passed the first review by an advisory committee to the health ministry in Japan.
Novo Nordisk said in a statement it expected to receive marketing authorization for the treatment from the Ministry within a few months.
Price negotiations for another insulin, degludec, continued and were expected to be completed in the first quarter of 2013, the company said in the statement, adding the exact launch timing for Ryzodeg would be decided after a price listing for degludec.
(Reporting by Copenhagen Newsroom; Editing by Hans-Juergen Peters)
- Texas man charged with capital murder for shooting dead six |
- Mexican train derails, stranding 1,300 migrants headed toward U.S.
- Palestinian death toll rises to 77 as Israel hits Gaza over rocket fire |
- Wall St. drops on Portugal bank worry; losses pared
- Berlin tells CIA station chief to leave in spy scandal